Articles

Cancer drugs: value is about more than cost

23rd October 2014

Cancer drugs: value is about more than costSue Mahony

When assessing the true value of cancer drugs, collaboration with key stakeholders, reform of the development process and reimbursement system, and a true understanding of what is important to the... Read more

NICE and the 2015 General Election

22nd October 2014

NICE and the 2015 General ElectionLeela Barham

What could the forthcoming UK General Election in May 2015 mean for the always evolving National Institute for Health and Care Excellence (NICE)? Leela Barham takes a look at how... Read more

Cutting-edge DNA sequencing to speed diagnostics

21st October 2014

Cutting-edge DNA sequencing to speed diagnosticsQuah Shun Ying and Syamala Ariyanchira

Next Generation Sequencing (NGS) technologies are allowing scientists to sequence DNA faster and expand knowledge of the genetic basis of disease. NGS is showing particular promise in areas where current... Read more

Social enterprises: doing NHS business without the bureaucracy

20th October 2014

Social enterprises: doing NHS business without the bureaucracy Nisha Desai

Nisha Desai, head of medicines management at social enterprise company Provide, speaks to pharmaphorum about how such organisations are benefitting the NHS, prior to her appearance at a major London... Read more

News

Increase NHS funding or face £30 billion shortfall, politicians warned

23rd October 2014

Increase NHS funding or face £30 billion shortfall, politicians warnedAndrew McConaghie

The health service in England will not be able to cope without billions in extra funding over the next five years, politicians have been warned.The stark warning comes from an... Read more

NICE draft guidance recommends Bayer’s Xarelto post heart attack

23rd October 2014

NICE draft guidance recommends Bayer’s Xarelto post heart attackLinda Banks

Draft guidance from UK health watchdog NICE recommends Bayer's rivaroxaban (Xarelto) for preventing blood clots in people who have had a heart attack as a result of a blockage or... Read more

FDA panel backs wider use of Vertex cystic fibrosis drug

22nd October 2014

FDA panel backs wider use of Vertex cystic fibrosis drugStaff reporter

More cystic fibrosis patients in the US should be eligible for treatment with Vertex Pharma's Kalydeco therapy, according to an FDA advisory committee.Yesterday the expert panel voted 13 to two... Read more

J&J to accelerate Ebola vaccine, open to collaboration with rivals

22nd October 2014

J&J to accelerate Ebola vaccine, open to collaboration with rivalsAndrew McConaghie

Johnson & Johnson is to spend $200 million on accelerating development of a new vaccine against the deadly Ebola epidemic.The company's vaccine is one of several currently in development aimed... Read more

Audio & Video

Live debate Oct 29th - Managing diabetes…

AHdiabweb300x200c


Non-adherence to self-management regimens in diabetes is globally a widespread, costly and ultimately life threatening issue. 

Reasons for non-adherence are complex... View more

On-demand webinar: Is pharma brand marke…

Kantar Health webinar


While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to... View more

View the conversation - Tweetchat: Manag…

Atlantis Healthcare diabetes Tweetchat


Working in partnership, Atlantis Healthcare and pharmaphorum conducted a Tweetchat focussed on the real world challenges patients face in managing... View more

Patient Opinion Leaders: Andrew Schorr

 

As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

White Papers

Pricing & Market Access Outlook 2014

Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need,... View info

Getting the most out of technology for m…

Getting the most out of technology for multichannel marketing

While every pharma company recognises the potential of multichannel marketing to optimize its engagement with prescribers, many are yet to implement it to maximum potential. IMS Health explains how a... View info

Anchoring qualitative methodologies in b…

Anchoring qualitative methodologies in business intelligence using smartphone appsPaul Mannu

The use of smartphone apps in market research enables genuine 'in the moment' insight to help us really understand behaviour. Combining this with qualitative methods gives us a deeper insight into behaviours... View info

Opportunities and challenges around non-…

Opportunities and challenges around non-adherence and self‑management in diabetesDr Sinéad NíMhurchadha and Stephen Galt

Diabetes is a chronic condition, the prevalence of which has been escalating around the world for years. The significant consequences this has for healthcare budgets and patient wellbeing is well... View info

Further News & Articles

Angel investors boost UK bioscience

New bioscience companies are set to benefit from greater access to angel backing thanks to an initiative to brin... Read more

News

AbbVie hits out at US Treasury as Shire bid dies

Following AbbVie's recommendation to its shareholders to vote against the takeover of Shire last week, Shire's b... Read more

News

UK experimental drugs bill 'could hit clinical trial recruitment'

Patients in England and Wales will be able to get access to experimental medicines from next March if a new b... Read more

News

Stem cell researchers closer to creating human organs

Researchers in the US have made functional intestinal tissue in the lab that could be used to test new drugs and... Read more

News

Parkinson’s charity pushes industry collaboration

Parkinson's UK has appointed pharma industry expert Dr Arthur Roach as its research director to increase coll... Read more

News

Regeneron's Eylea trumps rivals in NIH study

Regeneron is claiming victory after a US-government sponsored trial has suggested its eye treatment Eylea is sup... Read more

News